Finally, CTLA4Ig graduates to the clinic.
作者信息
Sayegh M H
机构信息
Laboratory of Immunogenetics and Transplantation, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
出版信息
J Clin Invest. 1999 May;103(9):1223-5. doi: 10.1172/JCI6952.
Abstract
摘要
相似文献
1
Finally, CTLA4Ig graduates to the clinic.
J Clin Invest. 1999 May;103(9):1223-5. doi: 10.1172/JCI6952.
2
CTLA4Ig-induced linked regulation of allogeneic T cell responses.
Transplant Proc. 2001 Feb-Mar;33(1-2):88-9. doi: 10.1016/s0041-1345(00)01917-5.
3
CD28, CTLA-4 and their ligands: who does what and to whom?
Immunology. 2000 Oct;101(2):169-77. doi: 10.1046/j.1365-2567.2000.00121.x.
4
Immunomodulation with intrathymic injection of donor splenocytes followed by CTLA4Ig therapy prolongs small intestinal allograft survival.
Transplant Proc. 1997 Feb-Mar;29(1-2):1065-6. doi: 10.1016/s0041-1345(96)00399-5.
5
Anti-CTLA-4 human scFv antibodies prevent T-cell activation in transplantation.
Transplant Proc. 2001 Feb-Mar;33(1-2):285-7. doi: 10.1016/s0041-1345(00)02012-1.
6
CTLA-4 is a second receptor for the B cell activation antigen B7.
J Exp Med. 1991 Sep 1;174(3):561-9. doi: 10.1084/jem.174.3.561.
7
The Yin and Yang of T cell costimulation.
Science. 1995 Nov 10;270(5238):932-3. doi: 10.1126/science.270.5238.932.
8
Blocking T-cell costimulation to prevent transplant rejection.
Transplant Proc. 1998 Aug;30(5):2146-9. doi: 10.1016/s0041-1345(98)00568-5.
9
Releasing the brakes on antitumor immune response.
Science. 1996 Mar 22;271(5256):1691. doi: 10.1126/science.271.5256.1691.
10
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.
J Clin Invest. 1999 May;103(9):1243-52. doi: 10.1172/JCI5857.
引用本文的文献
1
CTLA-4Ig (abatacept) balances bone anabolic effects of T cells and Wnt-10b with antianabolic effects of osteoblastic sclerostin.
Ann N Y Acad Sci. 2018 Mar;1415(1):21-33. doi: 10.1111/nyas.13643. Epub 2018 Mar 3.
2
Bone and the Immune System.
Toxicol Pathol. 2017 Oct;45(7):911-924. doi: 10.1177/0192623317735316. Epub 2017 Oct 18.
3
Physiological and pathophysiological bone turnover - role of the immune system.
Nat Rev Endocrinol. 2016 Sep;12(9):518-32. doi: 10.1038/nrendo.2016.91. Epub 2016 Jun 17.
4
CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model.
Arthritis Rheumatol. 2014 Apr;66(4):990-9. doi: 10.1002/art.38319.
5
The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis.
Scientifica (Cairo). 2013;2013:125705. doi: 10.1155/2013/125705. Epub 2013 Feb 3.
6
Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma.
Clin Exp Immunol. 2005 Jul;141(1):122-9. doi: 10.1111/j.1365-2249.2005.02815.x.
7
Psoriasis and the new biologic agents: interrupting a T-AP dance.
CMAJ. 2004 Jun 22;170(13):1933-41. doi: 10.1503/cmaj.1031335.
8
New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs.
Ann Surg. 2002 Nov;236(5):667-75. doi: 10.1097/00000658-200211000-00018.
9
Challenges to achieving clinical transplantation tolerance.
J Clin Invest. 2001 Oct;108(7):943-8. doi: 10.1172/JCI14142.
10
CTLA4 gene polymorphisms are associated with, and linked to, insulin-dependent diabetes mellitus in a Russian population.
BMC Genet. 2001;2:6. doi: 10.1186/1471-2156-2-6. Epub 2001 Mar 27.
本文引用的文献
1
Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413.
J Immunol. 2011 Oct 1;187(7):3466-74.
2
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.
J Clin Invest. 1999 May;103(9):1243-52. doi: 10.1172/JCI5857.
3
The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival.
J Immunol. 1999 Feb 15;162(4):1947-51.
4
Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model.
J Immunol. 1999 Jan 15;162(2):761-5.
5
Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment.
Transplantation. 1998 Nov 27;66(10):1387-8. doi: 10.1097/00007890-199811270-00021.
6
Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice.
J Immunol. 1998 Aug 15;161(4):1659-63.
7
The role of T-cell costimulatory activation pathways in transplant rejection.
N Engl J Med. 1998 Jun 18;338(25):1813-21. doi: 10.1056/NEJM199806183382506.
8
Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance.
J Exp Med. 1998 Jun 15;187(12):2037-44. doi: 10.1084/jem.187.12.2037.
9
Homeostasis and self-tolerance in the immune system: turning lymphocytes off.
Science. 1998 Apr 10;280(5361):243-8. doi: 10.1126/science.280.5361.243.
10
IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways.
J Immunol. 1998 Mar 1;160(5):2059-64.
Zotero 插件